有效的口服输送Teriparatide使用器官粘土-多聚甲酸纳米复合物用于骨质疏松症治疗
Gyu Lin Kim1, Yeon Ju Kang1, Soo Hwa Seo1
1College of Pharmacy, Dongguk University, Dongguk-ro-32, Ilsan-Donggu, Goyang 10326, Republic of Korea.
Pharmaceutics
|November 27, 2025
概括
一种使用pH响应纳米复合物 (EE/AC-Teri) 的新型口服配方成功地输送了teriparatide,增强了骨形成并抑制了骨质疏松症大鼠的再吸收. 这为骨质疏松症管理中注射提供了一个方便的替代方案.
科学领域:
- 制药科学 制药科学
- 生物材料工程 生物材料工程
- 纳米技术纳米技术
背景情况:
- 特里巴拉提德注射会引起不良事件和不便,限制患者的坚持.
- 骨质疏松症治疗需要改进药物输送系统,以改善患者的服药.
- 目前的治疗需要频繁注射,这对长期骨质疏松症管理构成挑战.
研究的目的:
- 开发一种对pH值有反应的 teriparatide 口服配方.
- 设计一种新的纳米复合物,用于增强 teriparatide 的口服输送.
- 通过口服途径克服皮下特里巴胺注射的局限性.
主要方法:
- 特里巴化物与多层酸盐 (AC) 自组合,形成AC-Teri纳米复合物.
- AC-Teri被涂上了Eudragit L100/S100,用于pH触发的释放 (EE/AC-Teri).
- 实验室释放,酶稳定性,Caco-2细胞透和骨质疏松性大鼠体内疗效都得到了评估.
主要成果:
- EE/AC-Teri表现出高封装效率 (>90%) 和依赖pH的药物释放.
- 该配方保护了teriparatide免受酶降解,并增加了Caco-2细胞透率的2.7倍.
- 口服EE/AC-Teri显著改善了骨质形成,并抑制了骨质疏松症大鼠的再吸收,恢复了骨架构.
结论:
- EE/AC-Teri是一种有前途的口服配方,用于皮胺的输送.
- 这种新的方法为治疗骨质疏松症的注射性特里巴胺提供了方便和有效的替代方案.
- 响应pH的纳米复合体技术有可能用于口服输送类药物.
相关概念视频
01:05Bioavailability Enhancement: Drug Stability Enhancement and GI Retention
332
Improving a drug's stability in the gastrointestinal (GI) tract is paramount for enhancing its bioavailability and therapeutic effectiveness. Various strategies are employed to protect the drug from the harsh gastric milieu and to ensure its release and absorption at the desired site within the GI tract.Polymer coatings are one such method used to shield drugs from the stomach's acidic environment. By preventing premature drug release, these coatings improve the bioavailability of unstable...
332
01:27Drug Delivery Systems: Different Types
406
Conventional oral drug products, termed immediate-release (IR) formulations, are engineered to promptly release their active pharmaceutical ingredient (API) upon ingestion, typically in tablets or capsules. This rapid release often results in swift drug absorption and consequent pharmacodynamic effects, although the timing and intensity can vary depending on the drug's properties. Prodrugs within these formulations require metabolic conversion to activate their pharmacodynamic effects,...
406
01:24Site-Targeted Drug Delivery Systems: Polymeric Carriers
160
Polymeric carriers enhance targeted drug delivery by increasing efficacy while minimizing off-target effects. These carriers comprise a biodegradable polymeric backbone integrated with functional elements that enable targeting, improve physicochemical properties, and regulate drug release.Targeting MechanismsThe targeting ability of polymeric carriers is mediated by a homing device, which is a molecular recognition component designed to selectively bind to specific tissues or cells. Monoclonal...
160
01:23Oral Drug Delivery Systems: Introduction
279
Oral drug delivery is the most common route of administration due to its convenience, cost-effectiveness, and high patient compliance. It enables precise formulation to ensure proper drug dosage and bioavailability. The development of oral dosage forms considers drug properties such as solubility, stability, and absorption to optimize therapeutic efficacy.Tablets, capsules, liquids, and chewable formulations enhance drug stability, mask undesirable tastes, and improve patient experience.
279
01:26Oral Drug Delivery Systems: Continuous-Release Systems
308
Continuous-release drug delivery systems offer a strategic approach to maintaining therapeutic drug levels over extended periods following oral administration. By modulating the release rate of active pharmaceutical ingredients, these systems minimize fluctuations in plasma concentrations, which enhances clinical efficacy and reduces the need for frequent dosing. Such characteristics make them particularly advantageous in managing chronic diseases where patient adherence and stable drug...
308
01:11Oral Drug Delivery Systems: Delayed-Release Systems
222
Delayed-release drug delivery systems are specialized pharmaceutical formulations designed to postpone the release of active compounds until the drug reaches a specific region of the gastrointestinal (GI) tract, typically the intestine. These systems are essential for drugs that may cause gastric irritation, are unstable in acidic environments, or need to exert therapeutic effects locally in the intestinal or colonic regions.The core feature of delayed-release systems is the use of enteric...
222